Page 1

RESPIRI ASX / MEDIA ANNOUNCEMENT 30 July 2021 June 2021 Quarterly Cash Flow and Quarterly Activities Report Respiri Limited ( ASX : RSH ) ( " Respiri " or the " Company " ) , an eHealth SaaS Company supporting respiratory health management , today announces the Appendix 4C quarterly cash flow and activities for the 3 month period ended 30 June 2021 . Operating Highlights During the quarter , Respiri continued to grow the Company's pharmacy banner group footprint for making wheezoⓇ available for sale to customers in retail settings . Respiri also commenced the rollout of its in - pharmacy education and patient engagement programs that are expected to aid with in - store pharmacist / patient engagement . These programs include the Respiri Connect Care Nurse team and the rollout of the Pharmacy Platform Group's asthma professional service program that was developed in conjunction with Respiri . In the quarter , wheezoⓇ was distributed to and made available by the Terry White Chemmart ( representing approximately 450 pharmacies ) and Sigma Healthcare pharmacy banner groups ( which includes Amcal , Guardian and others totalling more than 570 pharmacies ) . These additional blue chip organisations now take the total number of banner groups that sell wheezoⓇ to 14 , resulting in a retail footprint of approximately 1,600 pharmacies , which represents approximately 35 % of the total number of ex - hospital community pharmacies across Australia . To supply the additional stocking needs of this expanded pharmacy footprint , Cipla placed 2 orders for 1,000 wheezoⓇ devices ( 2,000 in total ) in the 30 June quarter . The payment from Cipla for the first April order was due in June , however cash was received in the 1st week of July and will be recorded in the 30 September Quarterly Report . To continue to bolster pharmacy sales and educational resources , Respiri engaged Hahn Healthcare to conduct sales force services . Hahn is a respected organisation whose services are used by pharmaceutical and healthcare companies to sell their products . Hahn will aim to get individual pharmacies that are not target clients for the Cipla sales force to purchase wheezoⓇ from their wholesaler . Hahn will also provide additional Connect Care Nurse services to accelerate the educational programs with pharmacies that are stocking wheezoⓇ . The Company has advanced discussions with potential marketing / distribution partners in the United States . The Company commissioned an independent expert evaluation of its wheezoⓇ device ( and associated app ) to assess its eligibility to qualify for Remote Patient Monitoring ( " RPM " ) Current Procedural Terminology ( " CPT " ) code reimbursement - : – a significant insurance reimbursement regime which exists in the US market . The expert , based in the United States , is an experienced advisor to US CPT coding committees and MACRA task forces . The Medicare Access and CHIP Reauthorization Act ( " MACRA " ) is a law that governs how the US federal government pays / reimburses physicians . In summary , the expert concluded that wheezoⓇ analyses breath sounds for the presence of a wheeze and that in the expert's opinion , breath sounds and wheezing are physiologic parameters . As physiological measures are a precondition for CPT reimbursement , the Board therefore expects that wheezoⓇ will qualify for Remote Patient Monitoring CPT code reimbursement when Respiri enters the US market . Respiri Limited | ABN 98 009 234 173 | Level 9 , 432 St Kilda Road , Melbourne VIC 3004 | Page 1